Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas
Condition: Acute Lymphoblastic Leukemia ,Lymphomas Intervention: Biological: Anti-CD19 CAR-T Sponsor: The First Affiliated Hospital of Nanchang University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Hospitals | Leukemia | Lymphoma | Research